• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Bristol-Myers Squibb Company

    4/15/25 5:00:48 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMY alert in real time by email
    DEFA14A 1 ef20047411_defa14a.htm DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 14A
     
    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.   )
     
    Filed by the Registrant ☒
    Filed by a Party other than the Registrant  ☐
    Check the appropriate box:
     
    ☐
    Preliminary Proxy Statement
     
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐
    Definitive Proxy Statement
     
    ☒
    Definitive Additional Materials

    ☐
    Soliciting Material under §240.14a-12
     
     Bristol-Myers Squibb Company
     (Name of Registrant as Specified In Its Charter)
     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
     
    Payment of Filing Fee (Check the appropriate box):
     
    ☒
    No fee required.
     
    ☐
    Fee paid previously with preliminary materials.
     
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
     


     Proxy Season Update  April 2025 
     

     2  Our Mission  To discover, develop and deliver innovative medicines that help patients prevail over serious diseases  Our Vision  To be the world's leading biopharma company  that transforms patients' lives through science   Our Values  • Integrity  • Innovation  • Urgency  • Passion  • Accountability  • Inclusion 
     

     Reshaping BMS to achieve sustained top-tier growth by the end of the decade, maximize long-term shareholder value and accelerate our ability to deliver breakthrough medicines to even more patients faster  3  Continued Pipeline Progress  23   Approvals from the FDA and other markets  20  Submissions  to the FDA   and other markets  1  New Molecular Entity  approved in 2024  30+  Early-stage  assets  In 2024, our Clinical and Regulatory Achievements Included:  * Opdivo Qvantig launched in January 2025 in the U.S.  Achieved U.S. approval and launched the first-in-class transformational treatment for adults with schizophrenia in the U.S. in decades  Achieved expanded approval in the E.U. & Japan to include the first-line treatment of adult patients with transfusion-dependent myelodysplastic syndromes-associated anemia  Achieved U.S. approval for subcutaneous formulation of nivolumab across most previously approved adult, solid tumor Opdivo indications *  Achieved U.S. approval and launched CAR T-cell therapy for relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma 
     

     Delivering sustainable Growth & Innovation in 2024  4  * Growth Portfolio includes:  & other Growth Products, including Onureg® (azacitidine), Inrebic® (fedratinib), Empliciti® (elotuzumab), and Nulojix® (belatacept), and royalty revenue.  ** Legacy Portfolio includes Eliquis® (apixaban), Revlimid® (lenalidomide), Pomalyst®/Imnovid® (pomalidomide), Sprycel® (dasatinib), Abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), and other mature brands.  † GAAP and non-GAAP diluted EPS include the net impact of Acquired IPRD charges and licensing income of ($6.39) in 2024 and ($0.28) in 2023. A reconciliation of GAAP to non-GAAP measures can be found on our website at bms.com. See “Quarterly package of financial Information” available on bms.com/investors for information on the list of specified items excluded from non-GAAP EPS.  Strong Commercial Performance  $48.3B  Total Revenues  in 2024  $22.6B  Growth Portfolio* net sales  compared to  $19.4B in 2023  $25.7B  Legacy Portfolio** net sales  compared to  $25.6B in 2023  ($4.41)  GAAP diluted EPS†  $1.15  Non-GAAP diluted EPS†  (85%) versus 2023  Completed Key Business Development Transactions, Including:  Acquisitions of Mirati Therapeutics, RayzeBio and Karuna Therapeutics; and  Global Strategic Collaboration Agreement with SystImmune  Balanced Capital Allocation Strategy  $15.2B  in cash flow from operating activities  5.3%  quarterly dividend increase for 2024  ~$6B  debt repayment  15th  consecutive year of annual increase 
     

     Committed to Sound Corporate Governance  5  Board Accountability & Shareholder Rights    Regular shareholder engagement    Limit on total board memberships for sitting CEO (2)    Annual election of Directors    Proxy access shareholder right    Majority voting standard for election of Directors    Ability to call special meetings (15%)    Robust Lead Independent Director role    No supermajority voting provisions for common stockholders    Annual Board and Committee evaluations    No stockholder rights plan    Regular assessment of Board composition    Extensive Related Party Transaction policies and procedures    Limit on public company board memberships for BMS Directors (4)    Semi-annual political contributions disclosures 
     

     Christopher S.  Boerner, Ph.D.  Theodore R.  Samuels  Peter J.  Arduini  Deepak L. Bhatt,  M.D., M.P.H., M.B.A.  Julia A.  Haller, M.D.  Manuel Hidalgo Medina,   M.D., Ph.D.  Board Chair & Chief Executive Officer of the Company  Lead Independent Director  (C)  (C)  (C)  More than 20 years of experience in the biotechnology industry, including prior roles at Bristol-Myers Squibb as Chief Commercialization Officer and Chief Operating Officer  Retired President of Capital Guardian Trust Company  President and Chief Executive Officer at GE Healthcare  Former President and CEO at Integra LifeSciences Holdings Corporation  Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai  Ophthalmologist-in-Chief of Wills Eye Hospital  Professor and Chair of the Dept. of Ophthalmology at Sidney Kimmel Medical College  Professor of Medicine and Chief of Division of Hematology and Medical Oncology at Weill Cornell Medical College  Attending Physician at New York-Presbyterian Hospital  Director Since: 2023  Director Since: 2017  Director Since: 2016  Director Since: 2022  Director Since: 2019  Director Since: 2021  Michael R.   McMullen*  Paula A.   Price  Derica   W. Rice  Karen H.   Vousden, Ph.D.  Phyllis R.  Yale  (C)  Former Chief Executive Officer of Agilent Technologies, Inc.  Former Executive Vice President & CFO of Macy’s, Inc.   Former Executive Vice President and CFO of Ahold USA  Former Chief Accounting Officer of CVS Caremark  Former Executive Vice President of CVS Health and President, Pharmacy Benefits Management Business of CVS Caremark  Former Executive Vice President of Global Services and CFO of Eli Lilly and Company  Principal Group Leader at the Francis Crick Institute in London  Former Chief Scientist at Cancer Research UK, Former Director of Beatson Institute for Cancer Research UK  Advisory Partner with Bain & Co.  Former Director of Blue Cross Blue Shield of Massachusetts  Director Since: 2024  Director Since: 2020  Director Since: 2020  Director Since: 2018  Director Since: 2019  Audit Committee   Committee on Directors & Corporate Governance  Compensation & Management Development Committee   Science & Technology Committee  (C) Committee Chair  * New Director since July 2024  2025 Board Nominees  6 
     

     Leadership  Strategic Thinking  Sound Business Judgment  Integrity & Ethics  Our Board Nominees Have a Comprehensive Collection of Varied Backgrounds, Industry Experiences & Personal Characteristics  7  Healthcare  Experience in relevant areas within the healthcare industry, including science, manufacturing, regulatory compliance, payer dynamics, and working with health care providers.  Science/Technology/Innovation  Relevant scientific expertise in the healthcare industry, and experience with technology and innovation, including the use of innovative technologies in the discovery, development and delivery of medicines.  Financial  Experience in corporate finance, and financial reporting and internal controls at a large organization.  Risk Management  Experience managing critical enterprise risks.  Sales & Marketing  Experience in commercialization, digital advertising, marketing and brand development.  International  Experience leading a complex global organization or understanding different regulatory and commercial requirements.  Public Company CEO/CFO  Experience serving as a CEO/CFO at a public or private company.  Academia/Non-Profit  Experience as professor, researcher or leader at a large university or non-profit organization.  Digital  Experience or expertise managing or overseeing information technology, including related to the use of digital technologies to facilitate business objectives, cybersecurity and data privacy.  Key Skills & Experience Definitions 
     

     Executive Compensation Supporting our Core Strategy  8  2024 CEO Target Pay Mix  CEO target compensation approximated the 35th percentile of our primary peer and PHRA Survey peer groups.  91%  78%  of target pay is  performance-based and at  risk  of target pay delivered in  long-term equity  Incentives with three-year  vesting  Average NEO Target Pay Mix (Excl. CEO)  Average NEO target compensation generally around the 75th percentile of our primary peer and PHRA Survey peer groups for the CFO and PHRA Survey peers only for other NEOs.  84%  68%  of average NEO target pay  is performance-based and  at risk  of average NEO target pay  delivered in long-term  equity incentives with  three-year vesting  Executive Compensation Philosophy & Principles  Competitive Compensation  Attracts, retains, and incentivizes talented executives capable of leading our business in a highly complex and competitive environment  Pay for Performance  A substantial proportion of our executives’ pay is variable and at-risk based on operational, financial, strategic, and share price performance, supporting alignment over the long term between our executives and our shareholders  Bristol Myers Squibb is an equal opportunity employer and all employment decisions are merit-based. The cornerstone of our compensation philosophy and program structure is aligning pay to the achievement of both our short-term and long-term goals, engagement of our employees, the achievement of our mission and the delivery of value to our shareholders.  As an organization, our priorities are to (i) focus on transformational medicines where we have a competitive advantage, (ii) drive operational excellence, and (iii) strategically allocate capital for long-term growth and shareholder returns.  Two Core Elements: 
     

     2024 Executive Compensation Program:Supporting Revenue Renewal and Execution of Our Core Strategy1  9  Base  Salary  Allows us to attract and retain talent in a highly competitive labor market  Based on specialized qualifications, experience and role impact, pay levels of comparable positions within peer group and competitive market  Annual Incentive  Non-GAAP  Operating Income  New for 2024  Critical measure of annual profitability, aligning our employees with our shareholders  No individual performance component. Payout based solely on the company performance  Growth Portfolio Revenue  New for 2024  Foundation of long-term sustainable growth and competitive superiority.  Increases focus on strategic priority of revenue renewal.  Pipeline  Near-Term Growth  Have evolved to:  Drive improved decision-making and operational rigor  Ensure alignment with company’s portfolio  Long-Term Growth Potential  Qualitative Overlay  Sustainability Scorecard  Aligned to our commitments on sustainability and social impact  Long-Term Incentive  (Paid in shares)  Performance Share Units  Rewards the achievement of financial goals and further aligns executive compensation with the interests of our shareholders — Non-GAAP Operating Margin (25%), Growth Portfolio Revenue (40%) and relative Total Shareholder Return CAGR (35%), each measured over an applicable three-year performance period.  Rewards the achievement of financial goals and further aligns executive compensation with the interests of our shareholders — Non-GAAP Operating Margin (25%), Growth Portfolio Revenue (40%) and relative Total Shareholder Return CAGR (35%), each measured over an applicable three-year performance period.  Market   Share Units  Rewards stock price appreciation, inclusive of the value of dividends accumulated during the performance period  Important component of attracting specialized talent  Rewards creation of incremental shareholder value  Promotes retention while maintaining pay-for-performance link  Rewards stock price appreciation, inclusive of the value of dividends accumulated during the performance period  Important component of attracting specialized talent  Rewards creation of incremental shareholder value  Promotes retention while maintaining pay-for-performance link  1 As an organization, our priorities are to (i) focus on transformational medicines where we have a competitive advantage, (ii) drive operational excellence, and (iii) strategically allocate capital for long-term growth and shareholder returns. 
     

     Executive Compensation Governance Practices  10  What We Do:  What We Don’t Do:    100% performance-based annual and long-term incentives  X  No guaranteed incentives with our Named Executive Officers    Caps on the payouts under our annual and long-term incentive award programs  X  Prohibition on speculative and hedging transactions    Robust share ownership and share retention guidelines  X  Prohibition on pledging shares and holding them in a margin account    Neutralize share buyback impact on share-denominated compensation metrics  X  Proactively eliminate windfall gain potential    Robust recoupment and clawback policies  X  No employment contracts with our Named Executive Officers    Proactive shareholder engagement  X  Prohibition on re-pricing or backdating of equity awards    “Double trigger” change-in-control agreements  X  Minimal perquisites to our Named Executive Officers 
     

     11  2025 Bristol Myers Squibb Board recommendations:  Management Proposals  Shareholder Proposals  FOR  Election of Directors  AGAINST  Shareholder Proposal on Corporate Financial Sustainability  FOR  Advisory Vote to Approve the Compensation of our Named Executive Officers  AGAINST  Shareholder Proposal on a Request to Cease DEI Efforts  FOR  Ratification of the Appointment of  an Independent Registered Public Accounting Firm  The Board Values Your Support at Our 2025 Annual Meeting 
     

     12  Accordingly, the Board of Directors unanimously recommends a vote “AGAINST” these shareholder proposals.  Shareholder Proposal on Corporate Financial Sustainability  Shareholder Proposal on a Request to Cease DEI Efforts  The Board has carefully considered this proposal and believes the actions requested are not in the best interests of the Company and its shareholders.  The Board has carefully considered this proposal and believes the actions requested are not in the best interests of the Company and its shareholders.  Our existing corporate governance practices are designed to maximize shareholder value and enable the successful implementation of our strategy.  The proposal seeks to duplicate oversight responsibilities already undertaken by the Board or delegated to its committees.  BMS publishes annual reports on its corporate responsibility and sustainability efforts.  Our commitment to inclusion, in compliance with applicable laws, furthers our strategic priorities and generates shareholder value.  Equal opportunity is a cornerstone of our culture. We prohibit workplace discrimination and retaliation and have a robust compliance program.  In sum, through its governance and Board oversight, the Company carefully considers how policy positions and actions impact long-term growth and shareholder value.   Our Board, therefore, believes that forming the committee requested by the proposal would be unnecessary and duplicative as it would not provide any additional oversight or information and would not be an effective use of the Company’s time and resources or benefit our shareholders. Our Board also believes that the requested report would be unnecessary and duplicative as the information is already largely available and thus would not benefit shareholders.  Our culture of inclusion enables us to create a respectful and welcoming work environment where all decisions are merit-based, and all employees are free to fully contribute and reach their maximum potential free from harassment and discrimination.   We regularly evaluate our practices to ensure compliance with law. We believe that our current practices are legally appropriate, crucial to fulfillment of Company strategy and valued by shareholders—nothing in the proposal demonstrates otherwise. As such, we do not believe this proposal to be in the best interests of the Company or its shareholders.  The Board Values Your Support at Our 2025 Annual Meeting 
     

     13  This presentation (as well as the oral statements made with respect to information contained in this presentation) contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Actual results may differ materially from those expressed in, or implied by, these statements as a result of various factors, including, but not limited to, (i) new laws and regulations, (ii) our ability to obtain, protect and maintain market exclusivity rights and enforce patents and other intellectual property rights, (iii) our ability to achieve expected clinical, regulatory and contractual milestones on expected timelines or at all, (iv) difficulties or delays in the development and commercialization of new products, (v) difficulties or delays in our clinical trials and the manufacturing, distribution and sale of our products, (vi) adverse outcomes in legal or regulatory proceedings, (vii) risks relating to acquisitions, divestitures, alliances, joint ventures and other portfolio actions and (viii) political and financial instability, including changes in general economic conditions. These and other important factors are discussed in the Company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q and current reports on Form 8-K. These documents are available on the U.S. Securities and Exchange Commission’s website, on the Company’s website or from Bristol-Myers Squibb Investor Relations. No forward-looking statements can be guaranteed.  In addition, any forward-looking statements and clinical data included herein are presented only as of the date hereof. Except as otherwise required by applicable law, the Company undertakes no obligation to publicly update any of the provided information, whether as a result of new information, future events, changed circumstances or otherwise. This presentation does not constitute a solicitation of a proxy, an offer to purchase or a solicitation of an offer to sell any securities.  This presentation includes certain non-Generally Accepted Accounting Principles (“GAAP”) financial measures that we use to describe the Company’s performance. The non-GAAP financial measures are provided as supplemental information and are presented because management has evaluated the Company’s financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the Company’s baseline performance, supplement or enhance management’s, analysts’ and investors’ overall understanding of the Company’s underlying financial performance and trends and facilitate comparisons among current, past and future periods. This presentation also provides certain revenues and expenses or other financial measures excluding the impact of foreign exchange (“Ex-FX”). We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. Ex-FX financial measures are not accounted for according to GAAP because they remove the effects of currency movements from GAAP results.   The non-GAAP information presented herein provides investors with additional useful information but should not be considered in isolation or as substitutes for the related GAAP measures. Moreover, other companies may define non-GAAP measures differently, which limits the usefulness of these measures for comparisons with such other companies. We encourage investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure. An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable financial measure are provided with this presentation and available on our website at www.bms.com/investors.  Also note that a reconciliation of forward-looking non-GAAP gross margin, non-GAAP operating margin, non-GAAP operating expenses and non-GAAP tax rate is not provided because a comparable GAAP measure for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. Namely, we are not, without unreasonable effort, able to reliably predict the impact of the unwind of inventory purchase price adjustments, accelerated depreciation and impairment of property, plant and equipment and intangible assets, and stock compensation resulting from acquisition-related equity awards, or currency exchange rates. In addition, the Company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results.  Forward Looking Statements and Non-GAAP Financial Information 
     

     


    Get the next $BMY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMY

    DatePrice TargetRatingAnalyst
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    4/22/2025Overweight
    Piper Sandler
    12/16/2024$70.00Hold → Buy
    Jefferies
    12/10/2024$63.00Neutral
    BofA Securities
    11/15/2024Peer Perform
    Wolfe Research
    11/13/2024Neutral → Outperform
    Daiwa Securities
    11/12/2024$73.00Market Perform → Outperform
    Leerink Partners
    10/25/2024$75.00 → $55.00Buy → Neutral
    Citigroup
    More analyst ratings

    $BMY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

      Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

      5/6/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Reports First Quarter Financial Results for 2025

      Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution   First quarter revenues were $11.2 billion, -6% (-4% Ex-FX) Growth Portfolio revenues were $5.6 billion, +16% (+18% Ex-FX) GAAP EPS was $1.20 and non-GAAP EPS was $1.80 Raising 2025 revenue guidance to a range of ~$45.8 billion to $46.8 billion; Increasing non-GAAP EPS range to $6.70 to $7.00 Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Sq

      4/24/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

      Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the threshold for a statistically significant difference compared to placebo with an atypical antipsychotic for the primary endpoint of the change from baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) total score Treatment with Cobenfy and an atypical antipsychotic showed a numerical improvement compared to treatment with placebo and an atypical antipsychotic Cobenfy's safety and tolerability profile as an adjunctive therapy was consistent with previous monotherapy trials Bristol Myers Squibb (NYSE:BMY) today announced topline results from the Phase 3 ARISE trial evaluating the efficacy and

      4/22/25 4:15:00 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/21/25 7:09:34 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/19/25 7:19:54 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

      For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

      9/26/24 6:42:20 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 14, 2024 - FDA Roundup: June 14, 2024

      For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

      6/14/24 3:54:45 PM ET
      $MMSI
      $BMY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • March 8, 2024 - FDA Roundup: March 8, 2024

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

      3/8/24 3:26:46 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Bristol-Myers with a new price target

      Cantor Fitzgerald initiated coverage of Bristol-Myers with a rating of Neutral and set a new price target of $55.00

      4/22/25 8:00:39 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Bristol-Myers

      Piper Sandler initiated coverage of Bristol-Myers with a rating of Overweight

      4/22/25 7:30:03 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol-Myers upgraded by Jefferies with a new price target

      Jefferies upgraded Bristol-Myers from Hold to Buy and set a new price target of $70.00

      12/16/24 6:45:40 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Leadership Updates

    Live Leadership Updates

    See more
    • Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

      Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

      5/6/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate

    $BMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP, Chief Commercial Officer Lenkowsky Adam

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      5/5/25 5:41:48 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Glob. Prod. Dev. & Supply Shanahan Karin converted options into 3,306 shares and covered exercise/tax liability with 1,692 shares, increasing direct ownership by 13% to 13,797 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/3/25 5:15:32 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Financials

    Live finance-specific insights

    See more
    • Bristol Myers Squibb Reports First Quarter Financial Results for 2025

      Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution   First quarter revenues were $11.2 billion, -6% (-4% Ex-FX) Growth Portfolio revenues were $5.6 billion, +16% (+18% Ex-FX) GAAP EPS was $1.20 and non-GAAP EPS was $1.80 Raising 2025 revenue guidance to a range of ~$45.8 billion to $46.8 billion; Increasing non-GAAP EPS range to $6.70 to $7.00 Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Sq

      4/24/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025

      Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2025 on Thursday, April 24, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company wh

      3/13/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Announces Dividend

      Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2025, to stockholders of record at the close of business on April 4, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on June 2, 2025, to stockholders of record at the close of business on May 6, 2025. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and d

      3/3/25 4:16:00 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    SEC Filings

    See more
    • Bristol-Myers Squibb Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      5/7/25 5:04:09 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Bristol-Myers Squibb Company

      10-Q - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      4/24/25 11:45:34 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol-Myers Squibb Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      4/24/25 7:11:41 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Bristol-Myers Squibb Company (Amendment)

      SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

      2/9/23 11:12:40 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bristol-Myers Squibb Company (Amendment)

      SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

      2/9/22 3:33:30 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

      2/10/21 10:39:37 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care